Skip to main content
OpenTrials
Completed

NCT Number: NCT01903291

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal response to glatiramer acetate (GA). The secondary objectives of this study in this study population are to assess the impact of DMF over a 12-month period on patient-reported outcomes (PROs) and health economic-related outcomes and to evaluate additional clinical outcomes at Month 12.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Relapsing Forms of Multiple Sclerosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Have the ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use Protected Health Information in accordance with national and local patient privacy regulations.
  • Have the ability to read and understand written English.
  • Have access to the internet and are able to complete online assessments on a computer
  • Have a relapsing form of Multiple Sclerosis and satisfy the approved therapeutic indication for dimethyl fumarate (DMF) per the United States Prescribing Information (USPI).
  • Are being treated for relapsing forms of multiple sclerosis (MS) with glatiramer acetate (GA) but, per the Prescribing Physician, have a suboptimal response (e.g., suboptimal efficacy, intolerance, or poor adherence) to GA or have stopped treatment with GA for relapsing forms of MS as a result of suboptimal response within 30 days of enrollment.
  • Have decided to initiate treatment with dimethyl fumarate (DMF) under routine clinical care. The decision to initiate treatment with DMF must precede enrollment.
  • Have a complete blood count (CBC) available within 6 months of initiation of treatment with dimethyl fumarate (DMF).

Key Exclusion Criteria:

  • Are unwilling or unable to comply with study requirements, or, are deemed unsuitable for study participation at the discretion of the Prescribing Physician.
  • Have major comorbid conditions that would preclude their participation in the study as determined by the Prescribing Physician.
  • Have a history of malignancy. (Patients with basal cell carcinoma that has been completely excised prior to study entry remain eligible.)
  • Have a history of and/or current serious infections.
  • Are pregnant or breastfeeding, or are planning to become pregnant or breastfeed.
  • Are receiving concomitant disease modifying therapies other than glatiramer acetate (GA) or have initiated treatment with a new disease-modifying therapy since discontinuation of glatiramer acetate (GA).
  • Are currently enrolled in any other clinical studies, with the exception of the dimethyl fumarate (DMF) Pregnancy Registry.
  • Have received prior treatment with dimethyl fumarate (DMF).

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Treatment and study plan

dimethyl fumarate

Drug

As described in the treatment arm

Other names: Tecfidera, BG00012, DMF

Primary outcomes

  1. Annualized Relapse Rate

    Time frame: 12 months

Secondary outcomes

  1. Change in 14-item Treatment Satisfaction Questionnaire for Medication (TSQM-14) scores.

    Time frame: Baseline to 12 months

    TSQM-14 is an instrument to assess patient's satisfaction with medication, providing scores on four scales: Side effects, effectiveness, convenience and global satisfaction.

  2. Change in Short-Form 36 (SF-36) scores.

    Time frame: Baseline to 12 months

    SF-36 is a self-administered, generic health status questionnaire consisting of 36 questions that measure 8 health concepts: physical functioning, role limitations due to physical problems, bodily pain, general health perception, vitality, social functioning, role limitations due to emotional problems and mental health.

  3. Change in Modified Fatigue Impact Scale (MFIS-5) scores.

    Time frame: Baseline to 12 months

    MFIS-5 is a modified form of the Fatigue Impact Scale that consists of five questions that assess the impact of fatigue on physical, cognitive, and psychosocial functioning, with five response levels ranging from 0 ("Never") to 4 ("Almost always"). Total scores range from 0 to 20, with higher scores representing a greater impact of fatigue.

  4. Change in Beck Depression Inventory (BDI-7) scores.

    Time frame: Baseline to 12 months

    BDI-7 is a self-report inventory for measuring the severity of depression on a 7-item scale.

  5. Change in Work Productivity and Impairment Questionnaire: Multiple Sclerosis (WPAI-MS) scores.

    Time frame: Baseline to 12 months

    The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

  6. Change in Morisky 8-item Medication Adherence Scale (MMAS-8) scores.

    Time frame: Baseline to 12 months

    MMAS-8 is a self-reporting tool to facilitate the identification of barriers to and behaviors associated with adherence to chronic medications. Scores on the MMAS-8 range from 0-8, with scores of less than 6 reflecting low adherence.

  7. Change in Patient-reported Expanded Disability Status Scale (patient-reported EDSS) scores.

    Time frame: Baseline to 12 months

    The patient-reported EDSS measures disability status based on patient report of degree of difficulty in eight different functional areas (on a 4-point scale), and overall function, taking into account the eight areas and descriptions of gait.

  8. Proportion of patients experiencing a relapse.

    Time frame: Baseline to 12 months

  9. Proportion of patients with relapses associated with hospitalizations.

    Time frame: Baseline to 12 months

  10. Proportion of patients with relapses associated with steroid use.

    Time frame: Baseline to 12 months

Sponsors and collaborators

Lead sponsor

Biogen

Industry

Registry information

Official study title

A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate

Acronym: RESPOND

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Jul 19, 2013
Registry last updated
Jul 25, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.